Browse Reports

Lingerie Fighting Championships, Inc. (LFC) is a sports entertainment company that produces and promotes live events and televised programming featuring predominantly female athletes engaging in wrestling and MMA fighting techniques for mature audiences. The company operates a reality series and sells branded merchandise such as apparel and DVDs. LFC has developed a substantial social media presence and has hosted numerous live events in the U.S. and Europe. The business model centers on event promotion, content production, and brand licensing, with distribution through digital, broadcast, and pay-per-view channels. LFC competes with larger sports entertainment entities like WWE and UFC, as well as other media entertainment providers. The company faces regulatory considerations related to event licensing and content distribution but is currently not regulated as a full contact sport [S1].

QHSLab, Inc. operates a digital health platform designed to assist independent primary care practices in identifying and managing behavioral health conditions and allergic diseases. The platform integrates into existing clinical workflows, enabling digital health assessments, risk stratification, automated documentation, and ongoing patient engagement outside traditional office visits. The company’s revenue model is based on recurring subscription and service fees charged to medical practices on a per-patient, per-month basis. The AllergiEnd® product line complements the platform by providing FDA-cleared allergy diagnostic devices and treatment services, allowing primary care providers to manage allergic diseases in-office. Target customers are typically small, independent physician-led practices that bill Medicare and commercial insurance. The company employs a focused sales strategy emphasizing capital efficiency and short sales cycles. QHSLab competes in a fragmented and competitive market with various digital health and allergy diagnostic providers. The company reported revenues of $2.7 million in 2025 with improving gross margins and a net income influenced by debt extinguishment gains. Liquidity metrics as of December 31, 2025, show a current ratio of 1.96 and cash ratio of 1.41. The company’s growth strategy includes expanding adoption among primary care practices and developing additional clinical domains and partnerships, subject to capital and regulatory factors.

BioScience Health Innovations, Inc., formerly known as Nowtransit Inc., rebranded to reflect its strategic focus on advanced health science innovations and proprietary delivery systems. The company operates primarily through its subsidiary Best 365 Labs, which markets a portfolio of clinically-tested, natural health and wellness products targeting bacterial, viral, mental health, and metabolic challenges. Key products include Be On-Guard sprays, brain support supplements, and patent-pending Methylene Blue formulations. The company emphasizes mitochondrial health as a preventive medicine approach and is developing the MODS Max digital platform to enhance direct-to-consumer sales and subscription services. Efforts to expand include upgrading e-commerce infrastructure, pursuing international registrations, and engaging pharmacy and clinical partners for broader distribution. Financially, the company has shown revenue growth and profitability in recent periods, with ongoing capital needs and market liquidity challenges due to its OTC Pink Market listing and penny stock status [S1][S2].

American Exceptionalism Acquisition Corp. A is a special purpose acquisition company formed to raise capital through an IPO to pursue a business combination with one or more target companies. Incorporated in the Cayman Islands, it completed its IPO in September 2025, issuing Class A ordinary shares and private placement shares to its sponsor. The proceeds from the IPO are held in a trust account pending the identification and completion of a business combination within a specified timeframe. The company has no operating history or revenue as of the latest filings and reports a net loss primarily related to operating expenses and costs associated with the IPO and formation activities.

Kenon Holdings Ltd. is a publicly traded holding company listed on the NYSE and TASE under the ticker KEN. The company operates mainly through two reportable segments: OPC Power Plants in Israel and CPV Group in the United States. OPC Power Plants focuses on generation and supply of electricity and energy in Israel, including development, construction, and operation of power plants. CPV Group operates renewable and conventional energy power plants in the United States. Kenon's business model centers on energy generation with a mix of renewable and natural gas assets. The company manages liquidity through operating cash flows, equity offerings, and debt financing, with a focus on compliance with financial covenants and maintaining sufficient liquidity to meet obligations. As of December 31, 2025, Kenon reported consolidated revenue of approximately $871.9 million USD and net income of $148.3 million USD, supported by strong liquidity metrics. The company has ongoing capital expenditures for project development and maintenance, including the Basin Ranch project in the U.S. Recent developments include OPC Energy enhancing its stake in power plants and securing additional funding.

AudioCodes Ltd. is an Israeli company specializing in voice communications technology for enterprises, contact centers, and service providers. Its offerings include voice networking infrastructure, cloud-based platforms, and Voice AI applications designed to support unified communications and contact center environments. The company’s solutions are structured across three layers: hardware devices and infrastructure, cloud platforms for provisioning and management, and AI applications for contact center and compliance functionalities. AudioCodes has a global presence, serving customers in over 100 countries through direct sales and a broad network of channel partners. The company has evolved from traditional VoIP hardware to include cloud-based managed services and AI-driven voice productivity tools. Its Live Platform enables cloud-based voice connectivity and AI services integration with major UCaaS providers such as Microsoft Teams, Webex, and Zoom. AudioCodes continues to invest in AI capabilities, expanding its portfolio with products like Meeting Insights, Interaction Insights, and Voca CIC, which leverage conversational AI and large language models to enhance customer engagement and operational efficiency. The company reported fiscal year 2025 revenue of $245.6 million and net income of $8.96 million, with solid liquidity metrics. It faces competitive pressures from established telecommunications equipment providers and is subject to macroeconomic and geopolitical risks impacting supply chains and technology adoption.

Allurion Technologies, Inc. is an emerging growth company known for its Allurion Gastric Balloon System, which received FDA PMA approval in early 2026. The company operates in the medical product sector, focusing on weight management solutions. Despite regulatory progress, the company faces significant financial challenges, including a substantial net loss and liquidity constraints as reflected in its low current and cash ratios. The company’s common stock was delisted from the NYSE in March 2026 due to non-compliance with market capitalization requirements and is currently trading on the OTCID Market while appealing the delisting decision. Capital structure adjustments have been made through warrant inducement transactions to improve financial flexibility.

MeiraGTx Holdings plc operates as a vertically integrated genetic medicines company focused on developing and commercializing gene therapy products. The company has developed a proprietary riboswitch gene regulation platform enabling precise control of gene expression via oral small molecules. It owns two GMP-compliant viral vector manufacturing facilities in London and Shannon, supporting clinical and commercial supply. MeiraGTx's pipeline includes late-stage clinical programs for radiation-induced xerostomia, Parkinson's disease, and inherited retinal dystrophies, among others. Strategic collaborations with Johnson & Johnson, Hologen Limited, and Eli Lilly support research, development, manufacturing, and commercialization efforts. The company also acquired Smart Immune's assets to expand into cell therapy. Financially, MeiraGTx reported $81.4 million in revenues and a net loss of $114.2 million for 2025, with liquidity ratios indicating moderate short-term financial flexibility.

Ondas Holdings Inc operates in the communication equipment industry, providing wireless and unmanned aerial systems (UAS) data solutions primarily to critical infrastructure, defense, public safety, and government sectors. The company develops technology compliant with evolving wireless broadband standards and aims to expand its market presence through organic growth and acquisitions. Ondas has a concentrated customer base and relies significantly on government contracts, which are subject to budgetary and regulatory uncertainties. The company maintains strong liquidity with substantial cash reserves and current assets exceeding current liabilities by a wide margin as of the end of 2025.

Scienture Holdings, Inc. is a specialty pharmaceutical company operating through its wholly owned subsidiary Scienture LLC, which focuses on the commercialization and development of products for cardiovascular and central nervous system diseases. Scienture LLC launched its first commercial product, Arbli™ (SCN-102), an FDA-approved oral liquid formulation of losartan potassium for hypertension and related indications, in the third quarter of 2025. The company also acquired REZENOPY™, a naloxone nasal spray product, and holds exclusive U.S. commercialization rights. The product portfolio includes FDA-approved and pipeline candidates targeting CNS and CVS conditions, with ongoing clinical development and regulatory activities. Scienture LLC's strategy includes advancing product candidates through clinical studies, driving growth via dedicated sales and marketing, pursuing strategic business development opportunities, and expanding its development pipeline through internal R&D and partnerships [S1].

Pulsenmore Ltd. develops and markets innovative, non-invasive portable ultrasound devices designed for home use, enabling patients to perform self-scans with telehealth support. Its primary products include the Pulsenmore ES for prenatal care, the Pulsenmore FC for follicular monitoring in IVF and fertility preservation, and the Pulsenmore MC in early development for pulmonary fluid monitoring. The company’s products are approved in multiple international markets and leverage proprietary ultrasound technology integrated with smartphone applications to facilitate remote monitoring and consultation. Pulsenmore’s business model includes direct sales to healthcare providers and partnerships with major Israeli health organizations, with a growing focus on expanding commercial presence in the United States following FDA clearance. The company maintains a robust intellectual property portfolio and a manufacturing process compliant with international quality standards. Pulsenmore’s strategy emphasizes expanding geographic reach, enhancing product offerings, and developing recurring revenue streams through software services.

ECARX Holdings Inc. develops and supplies automotive computing platforms and software solutions globally. Its product portfolio includes infotainment head units, digital cockpits, autonomous driving control units, and vehicle chipsets. The company serves a diversified customer base including Geely Holding and other automotive OEMs and Tier 1 suppliers. ECARX’s revenue streams comprise sales of goods, software licensing, and services such as design and development and connectivity. The company maintains a significant R&D focus with approximately 70% of its 1,400+ employees engaged in research and development across multiple global locations. ECARX has expanded its in-house production capabilities and made strategic acquisitions to support growth. It has established partnerships with Qualcomm and Samsung to advance automotive intelligence technologies and software-defined vehicles. The company faces competitive industry dynamics and regulatory requirements in China related to foreign investment and intelligent connected vehicle testing.

HCM IV Acquisition Corp. is a Cayman Islands exempted blank check company (SPAC) formed in September 2025 to effect a business combination with one or more target companies. The company completed its IPO in February 2026, raising gross proceeds of $287.5 million, which are held in a trust account invested in low-risk securities. The company has not commenced operations or generated revenues as of the latest filing and has not identified any business combination target. The Sponsor holds founder shares and private placement warrants and has agreed to waive certain redemption rights. The company faces competition from other SPACs and investment entities in identifying suitable targets. The management team has experience in acquisitions and growth investing but there is no assurance of completing a business combination. The company is an emerging growth company with limited operating history and financial data.

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company engaged in the development of novel drug candidates, primarily brilaroxazine, targeting schizophrenia and potentially other neuropsychiatric disorders. The company has completed Phase 2 and Phase 3 clinical trials for brilaroxazine, including the RECOVER and REFRESH studies, with positive safety and efficacy data reported. Reviva is advancing regulatory interactions with the FDA, including a recommended second Phase 3 trial for schizophrenia. The company has recently raised capital through a $10 million public offering and implemented a reverse stock split to address Nasdaq listing requirements. Financially, Reviva reported a net loss for fiscal year 2025 and maintains liquidity sufficient to fund operations into early 2027. The company faces risks related to Nasdaq compliance, regulatory approval timelines, and the need for additional capital to support ongoing and planned clinical trials.

HCM III ACQUISITION CORP. is a Cayman Islands exempted blank check company incorporated in April 2025. It was formed to effect a merger, share exchange, or similar business combination with one or more target companies. The company completed its IPO in August 2025, issuing 25.3 million units and raising $253 million, which was placed in a trust account invested in U.S. government securities. The Sponsor holds founder shares and has agreed to certain obligations to protect trust account funds. The company had not commenced operations as of December 31, 2025, and generates no operating revenues until after completing its initial business combination. The company completed a business combination with Murano PV, S.A. DE C.V., a Mexican development company, as announced in March 2024. The management team has experience in acquiring assets at disciplined valuations and aims to complete a business combination with an established business of scale. The company is subject to Nasdaq rules requiring the business combination to have a fair market value of at least 80% of trust assets and to acquire controlling interest in the target. Public shareholders have redemption rights upon completion of the business combination. The company is an emerging growth company and a smaller reporting company, eligible for certain reduced disclosure obligations.

Gores Holdings X, Inc. / CI is a special purpose acquisition company (SPAC) that completed its IPO in May 2025, raising approximately $358.8 million. The company’s business model is to identify and complete an initial business combination with one or more target businesses. It currently holds funds in a trust account and has no operating revenues or history. The company’s sponsor and management have significant influence over the business combination process, including voting rights. Liquidity as of the end of 2025 is limited, with current liabilities exceeding current assets. The company is subject to various risks inherent to blank check companies, including potential conflicts of interest and limited shareholder control over the initial business combination.

21Shares Solana ETF is a Delaware statutory trust formed in 2024 that issues shares representing fractional interests in a portfolio primarily composed of SOL tokens, the native digital asset of the Solana blockchain. The Trust is a passive investment vehicle that seeks to track the performance of SOL as measured by a specified pricing benchmark, adjusted for expenses and liabilities. The Trust may stake a portion of its SOL holdings to earn rewards, which are distributed to shareholders after fees. Shares are created and redeemed in large blocks (Creation Baskets) through authorized participants, with transactions facilitated by a Prime Broker and multiple SOL Custodians. The Trust is not registered as an investment company under the Investment Company Act and is not regulated as a commodity pool. The Sponsor, a subsidiary of 21co Holdings Limited and ultimately FalconX Holdings Limited, manages the Trust's marketing, registration, and fee arrangements but does not exercise day-to-day control over custodians or trustees. The Trust calculates NAV daily based on the Pricing Benchmark and follows fair value accounting standards for SOL. The Trust reported a net loss of approximately $4.15 million for the fiscal year ended December 31, 2025.

Enlight Renewable Energy Ltd. is a renewable energy platform founded in 2008 and publicly listed on Nasdaq since 2023 and on the Tel Aviv Stock Exchange since 2010. The company develops, finances, constructs, owns, and operates utility-scale renewable energy projects, primarily solar and wind, across multiple geographies including Israel, Europe, the United States, and the MENA region. Revenue is mainly generated from electricity sales under long-term power purchase agreements (PPAs) with terms ranging from 5 to 30 years, supplemented by some merchant sales and revenues from green certificates and services. Enlight controls the full project life cycle, enabling strategic capital allocation and operational management. The company has demonstrated growth through new project additions and geographic expansion, including recent investments in energy storage projects in Europe and the U.S. Financing is sourced through project finance debt, equity offerings, and tax equity partnerships. The company faces operational and geopolitical risks, including the ongoing conflict in Israel and regulatory requirements in the U.S.

Electra Battery Materials Corp is a Canadian company specializing in the refining and recycling of battery materials, primarily cobalt, nickel, lithium, manganese, and graphite, for the electric vehicle market. The company operates a hydrometallurgical refinery in Ontario, Canada, and holds mineral properties in the Idaho Cobalt Belt, including the Iron Creek Project. Electra's business model centers on producing battery-grade materials from both mining feedstock and recycled battery scrap (black mass) using proprietary hydrometallurgical processes. The company has established long-term supply contracts with Glencore and offtake agreements with Stratton Metals and LGES. Electra is in the advanced stages of constructing and commissioning its refinery, with a US$73 million budget approved in early 2026 and plans for commercial production in late 2027. The company has received government funding commitments and is actively managing capital needs through private placements and debt restructuring. Electra is publicly listed on the TSX Venture Exchange and Nasdaq under the ticker ELBM.

REED'S, INC. is a branded beverage company specializing in natural, premium, and functional beverages under the Reed's and Virgil's brands. Its products, numbering around 50, are distributed through a network of seven independent manufacturers and five distribution centers, reaching over 32,000 outlets in the U.S. and Asia-Pacific. The company emphasizes real ginger, clean-label ingredients, and functional formulations, competing in the U.S. carbonated soft drink market. It operates an asset-light model relying on co-packers and distributors to scale production efficiently and manage costs. The product portfolio includes craft ginger beers, real ginger ales, handcrafted sodas, functional sodas with adaptogens, and ready-to-drink alcoholic beverages. Distribution channels span natural and specialty wholesale distributors, direct-store-delivery, warehouse delivery, and wholesale distribution. Key customers include major natural food retailers, grocery chains, club stores, liquor stores, and convenience outlets. The company has expanded its international presence with subsidiaries in Asia-Pacific. It faces competition from large beverage companies and regional producers in both non-alcoholic and RTD alcoholic beverage segments. The company reported a net loss of $15.842 million for fiscal 2025 and maintains liquidity with a current ratio of 1.6. It carries a Senior Secured Loan due in September 2026, secured by most assets, with refinancing risks noted. Recent news reports indicate a 20% sales drop and Q2 losses in 2025, highlighting operational and market challenges.

Armata Pharmaceuticals, Inc. focuses on developing high-purity, pathogen-specific bacteriophage therapeutics as alternatives to traditional antibiotics for treating antibiotic-resistant and difficult-to-treat bacterial infections. The company’s proprietary technology enables targeting of specific bacteria while preserving the human microbiome. Armata has completed three Phase 2 clinical trials, including studies of inhaled AP-PA02 for chronic pulmonary infections caused by Pseudomonas aeruginosa in cystic fibrosis and non-cystic fibrosis bronchiectasis patients, and intravenous AP-SA02 for complicated Staphylococcus aureus bacteremia. The company has enhanced manufacturing processes to produce high-titer, high-purity phage products with lot-to-lot consistency, supporting potential commercialization. Armata operates manufacturing and R&D facilities in California and Australia. The company’s stock trades on the NYSE American under the ticker ARMP.

Planet 13 Holdings Inc. operates as a vertically integrated cannabis cultivator, producer, distributor, and retailer across Nevada, California, Illinois, and Florida. The company holds multiple cultivation, production, distribution, and dispensary licenses in these states. Its flagship retail location is the Planet 13 Las Vegas Superstore, a large dispensary with entertainment features. The company also operates several other dispensaries and manufacturing facilities, offering products under several proprietary brands. Planet 13 maintains a significant customer loyalty database and engages in wholesale and retail cannabis sales. The company’s operations are subject to extensive regulatory compliance and industry-specific risks.

EDAP TMS SA develops and markets minimally invasive medical devices using robotic energy-based ultrasound technology. Its core product, the Focal One® HIFU system, is designed for focal therapy of prostate cancer and has potential applications in other urological and gynecological conditions. The company combines imaging, robotics, and precise energy delivery to offer non-invasive treatment options. EDAP has a growing global install base, including a significant presence in the U.S. market, supported by clinical evidence and reimbursement frameworks. The company’s financials show revenue growth in its core HIFU segment alongside ongoing net losses reflecting investment in growth and innovation.

Equillium, Inc. is a clinical-stage biotechnology company incorporated in 2017, engaged in the research and development of novel biopharmaceutical product candidates, primarily EQ504 and EQ302. The company has not yet achieved regulatory approval for any product and has no commercial revenues. Its operations include clinical and preclinical development, in-licensing of product rights, and business development activities. Equillium relies on third-party manufacturers and CROs for production and clinical studies. The company completed a private placement in 2025 to raise capital for advancing clinical trials, particularly a Phase 1 study for EQ504. Equillium faces significant risks including ongoing operating losses, the need for substantial additional funding, regulatory uncertainties, and the challenge of establishing commercialization capabilities. The company also navigates risks related to international trade policies and geopolitical factors affecting its supply chain.

Dyadic International Inc operates in the biotechnology sector with a focus on microbial protein production platforms and related technologies. The company has been advancing its alternative proteins business and vaccine development efforts, including securing grants for antibody development. In 2025, Dyadic announced a strategic shift towards the ancillary protein market and underwent leadership changes. The company reported significant revenue growth in Q2 2025 and has been narrowing its losses. Dyadic maintains liquidity with cash, short-term investments, and a current ratio above 2. The company has faced Nasdaq listing compliance challenges related to minimum bid price and market value of listed securities but has regained compliance and is actively monitoring its status. Capital raising efforts include an at-the-market equity offering program.

Gulf Coast Ultra Deep Royalty Trust holds overriding royalty interests in the onshore Highlander subject interest, targeting deep hydrocarbon formations in South Louisiana. The trust's income derives from royalties on production, but it does not operate or control the underlying assets. The only producing well was shut in and abandoned in early 2024, and future income depends on successful drilling and production from new wells. The trust relies on contributions and loans from HOGA to cover administrative expenses and maintain liquidity. The trust units trade on an OTC market with limited liquidity and are subject to penny stock regulations.

Toppoint Holdings Inc. operates as a truckload services and solutions provider specializing in the recycling export supply chain. The company transports waste paper, scrap metal, and wooden logs from large waste companies, recycling centers, and commodity traders to ports in Newark, NJ and Philadelphia, PA. It also provides import transportation services at these ports, moving cargo-filled containers to customer locations. Toppoint has expanded its footprint domestically into Florida and Maryland markets and internationally into Mexico and Texas, with plans to explore Latin America, including Peru. The company serves a broad client base including Fortune 500 waste companies and over 207 recycling centers and commodity traders across more than 1,000 locations. Toppoint emphasizes integrated transportation solutions and high-quality service. The company completed its initial public offering in January 2025, raising $10 million. It operates one reportable segment and evaluates performance primarily through net income.

SOLV Energy, Inc. is a publicly traded company on Nasdaq (ticker MWH) that completed its initial public offering in early 2026. The company is engaged in the clean energy sector, advancing solar energy projects such as the Blossom Solar Project in Ohio and the Nightfall Solar Project in Texas. It filed an amended annual report (10-K/A) for the fiscal year ended December 31, 2025, which includes standard regulatory disclosures and auditor consents. The company has publicly reported its financial results for 2025 and maintains active communication through press releases.

MODIV INDUSTRIAL, INC. is a real estate investment trust primarily engaged in acquiring, managing, and disposing of industrial properties. The company’s portfolio includes properties leased to tenants such as Fujifilm Dimatix, Inc. and Northrop Grumman Systems Corporation, with lease terms extending several years. It utilizes a credit facility comprising a revolving line of credit and a term loan, with interest rate swaps to manage exposure to floating rates. The company actively manages its portfolio through acquisitions and dispositions, including a recent acquisition in Jacksonville, Florida, and sales of properties in New York and Washington. Capital expenditures focus on tenant improvements and property maintenance. The company reports operating performance using Funds from Operations (FFO) and Adjusted Funds from Operations (AFFO) metrics. Market conditions such as inflation, interest rates, and supply chain disruptions are acknowledged as ongoing challenges [S1][N1][N4].

Medicus Pharma Ltd. is a biotechnology company focused on accelerating clinical development of novel therapeutic assets. Its key product candidates include SkinJect, a patch technology for non-invasive treatment of basal cell carcinoma, and Teverelix, a drug candidate for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention episodes due to enlarged prostate. The company acquired Antev in 2025, which added Teverelix to its pipeline. Medicus Pharma is in early clinical stages with ongoing Phase 2 trials and has no current product revenues or customer contracts. The company relies on external contract research organizations and is building its operational and commercial capabilities. It is listed on Nasdaq and recently celebrated its one-year anniversary on the exchange.

Nkarta, Inc. pioneers the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies, aiming to provide broadly accessible treatments for autoimmune diseases. The company's lead candidate, NKX019, is a CAR NK cell therapy targeting CD19, currently in Phase 1 trials for multiple autoimmune indications including lupus nephritis, systemic sclerosis, and myasthenia gravis. Nkarta's platform leverages healthy donor NK cells, enabling scalable manufacturing and potential outpatient administration. The company has proprietary technologies addressing NK cell expansion, engineering, persistence, and cryopreservation challenges. Nkarta operates two cGMP manufacturing facilities in South San Francisco to support clinical and potential commercial supply. The company has incurred significant losses since inception and continues to invest in clinical development and manufacturing capabilities [S1].

WidePoint Corp is a provider of Technology Management as a Service (TMaaS) solutions that include federally certified communications management, identity management, interactive billing and analytics, and Information Technology as a Service (ITaaS). The company serves primarily U.S. federal government agencies, including the Department of Homeland Security, and commercial enterprises. Its TMaaS offerings are delivered through a flexible 'As-a-Service' model designed for scalability and configurability. WidePoint's managed services encompass telecom lifecycle management, mobile and identity management, digital billing and analytics, and IT services such as cybersecurity, cloud, and network operations. The company holds multiple government contracts and contract vehicles, including the DHS Cellular Wireless Managed Services 2.0 ID/IQ contract and the Navy Spiral 4 contract. WidePoint operates proprietary solutions hosted in multiple data centers in North America and Europe, with plans to migrate more customers to the cloud. The company competes in a fragmented market with various competitors across its service segments but claims a competitive advantage by offering all four critical TMaaS services. Sales approaches include direct sales, partnerships with large systems integrators, and strategic partnerships leveraging reseller networks. The sales cycle is typically long, often exceeding 12 months from initial engagement to contract award and implementation. Financially, WidePoint reported $150.5 million in revenue for fiscal year 2025, with a net loss of $2.75 million and a gross margin of 14%. The company maintains a revolving credit facility and reported positive operating cash flow in 2025.

TELA Bio, Inc. develops and commercializes innovative soft-tissue reconstruction solutions designed to optimize clinical outcomes by preserving and restoring the patient’s own anatomy. Its flagship products, the OviTex and OviTex PRS reinforced tissue matrices, combine biologic material derived from ovine rumen with polymer fibers to provide strength, stability, and controlled stretch for use in hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery. The company’s products are FDA-cleared and manufactured exclusively by Aroa in New Zealand under a long-term supply agreement. TELA Bio markets primarily in the U.S. through a direct sales force and has established contracts with national group purchasing organizations and integrated delivery networks to increase hospital access. The company invests in clinical studies and product development to enhance its portfolio and expand indications. Financially, TELA Bio reported $80.3 million in revenue and a net loss of $38.8 million for the year ended December 31, 2025, with strong liquidity ratios indicating a solid short-term financial position [S1].

Immersion Corporation is a publicly traded company incorporated in Delaware, with its common stock listed on the Nasdaq Global Market under the symbol IMMR. The company is headquartered in Aventura, Florida. It operates within the computer peripheral equipment industry, as indicated by recent industry-focused news coverage. The company maintains a strong liquidity position with current assets significantly exceeding current liabilities as of the latest quarterly report. It reported a net loss and negative earnings per share for the quarter ended July 31, 2025. The Board has declared a quarterly cash dividend, reflecting a capital allocation strategy that includes shareholder returns. Immersion has a history of filing detailed SEC reports including annual and quarterly filings with comprehensive disclosures on financials, governance, and securities.

United Security Bancshares is a bank holding company headquartered in Fresno, California, operating through United Security Bank. The Bank provides a comprehensive range of commercial banking services including deposit accounts, lending products such as commercial, real estate, construction, agricultural, and consumer loans, and specialized services like online and mobile banking. The Bank's operations are concentrated in Fresno, Madera, Kern, Santa Clara, and other California counties, competing with numerous financial institutions. The company maintains regulatory compliance under the Federal Reserve Board, California DFPI, and FDIC insurance. The loan portfolio is diversified but has a high concentration in commercial real estate loans. The company also manages real estate holdings through a subsidiary and has issued Trust Preferred Securities via a special purpose entity. The company’s stock is listed on Nasdaq under the ticker UBFO.

Leef Brands Inc. is a publicly traded cannabis company headquartered in California, listed on the Canadian Securities Exchange under the ticker LEEF. The company operates a vertically integrated business model encompassing cultivation, extraction, manufacturing, and retail. Its core operations include a large-scale cultivation property, Salisbury Canyon Ranch, with 179.9 licensed acres, and advanced extraction facilities with ethanol, hydrocarbon, and solventless extraction capabilities. Leef Brands supplies bulk cannabis concentrates, including distillates, live resin, and rosin, primarily to licensed cannabis brands in California and New York. The company holds multiple state licenses, including a Type 7 manufacturing license in California and a Type 1 processor license in New York. Leef Brands has expanded extraction capacity and entered the New York market, reporting revenue growth and margin expansion in 2025. The company also pursues a Bitcoin treasury strategy, accumulating Bitcoin organically through operations. It employs approximately 81 full-time employees and operates one retail location that does not materially contribute to revenue.